PNV mentioned on the trade (******) today. Both Jun Bei from tribeca and another guy from Shaw I think canned PNV in favour of ARX. both suggested PNV over valued and more runway for ARX (Aroa)
The Shaw Partners investor suggested ARX product had longer shelf life and less issue with infection. Has he got his info around the wrong way?? I thought PNV would have longer shelf life (not biological) and I am pretty sure that PNV has market leading results around infection? Have I got my details wrong?
PNV mentioned on the trade (******) today. Both Jun Bei from...
-
- There are more pages in this discussion • 7,743 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35541 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 2681 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |